Applications of Cryopreserved Human Dissociated Tumor Cells (DTCs) for Drug and Diagnostic Development, Upcoming Webinar Hosted by Xtalks

Share Article

In this free webinar, explore the applications of cryopreserved human dissociated tumor cells (DTCs) for drug and diagnostic development. Attendees will learn about the generation of the world’s largest cryopreserved dissociated tumor biobank for large scale biomarker discovery programs. The featured speaker will discuss the optimization of workflows to achieve maximum utility from valuable tissue samples, the establishment of in vitro culture systems to determine cellular responses to experimental drug compounds, and the evaluation of novel targets and biomarkers using DTCs in solid tumor indications.

These specimens provide the opportunity to screen for novel biomarker expressions including the expression patterns of the programmed cell death protein-1/ programmed cell death ligand-1 (PD1/PDL1) pathway.

The acquisition of fresh human tissue is often an impediment to significant research advances. As an alternative, Discovery Life Sciences offers cryopreserved human dissociated tumor cells (DTCs) and tissues as a viable specimen source for many downstream applications, including immunophenotyping, bulk and single-cell sequencing, and single-cell functionality. Extensive cellular profiling of DTCs by flow cytometry revealed indication-specific trends in the composition of the tumor microenvironment. Additionally, these specimens provide the opportunity to screen for novel biomarker expressions including the expression patterns of the programmed cell death protein-1/ programmed cell death ligand-1 (PD1/PDL1) pathway.

Workflow optimizations and the integration of a large DTCs biobank with a full scale cell services laboratory provide improved assay performance and shortened study timelines. Finally, as viable cell suspensions, dissociated human tissues can be utilized in both short-term and long-term cultures, and the functionality of tumor-infiltrating T cells can be evaluated using IsoPlexis single-cell proteomic pipelines. Collectively, cryopreserved dissociated human tissue combined with cellular and proteomic services allow for a multifaceted analysis of the next generation of cancer therapies.

Register to learn about the applications of cryopreserved human dissociated tumor cells (DTCs) for drug and diagnostic development.

Join Shawn Fahl, PhD, VP Lab Operations, Cell Services & R&D, Biospecimens, Discovery Life Sciences, for the live webinar on Monday, November 7, 2022, at 9am EST (3pm CET/EU-Central).

For more information, or to register for this event, visit Applications of Cryopreserved Human Dissociated Tumor Cells (DTCs) for Drug and Diagnostic Development.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:
Vera Kovacevic
Tel: +1 (416) 977-6555 x371
Email: vkovacevic@xtalks.com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Vera Kovacevic
Xtalks
+1 (416) 977-6555 x371
Email >
Visit website